Lonnie Shoff - Henry Schein CEO

HSIC Stock  USD 74.18  0.40  0.54%   

CEO

Ms. Lonnie Shoff serves as Chief Executive Officer Global Strategic Portfolio Group. She previously served as Chief Executive Officer of Global Animal Health and Strategic Partnership Group of Henry Schein, Inc., since 2012. Ms. Shoff is also a member of our Executive Management Committee. In this position, Ms. Shoff oversees our Global Animal Health business, which serves veterinary customers in the United States, 11 countries across Europe, Australia and New Zealand. She also oversees our Global Dental Specialties Group and a growing portfolio of joint ventures. Prior to holding her current position, Ms. Shoff was President of our Global Healthcare Specialties Group since 2009. Prior to joining us, Ms. Shoff was with Roche Diagnostics, where she held a series of positions of increasing responsibility in the United States and Switzerland over the course of 20 years, most recently as Senior Vice President and General Manager, Applied Science, focusing on applied science, molecular diagnostics, global business development, and marketing and business management, including leading the U.S. commercial operations for this 350 million group since 2015.
Age 56
Tenure 9 years
Address 135 Duryea Road, Melville, NY, United States, 11747
Phone631 843 5500
Webhttps://www.henryschein.com
Shoff has managed the life cycles of more than 2, 500 products, launched several novel technologies and nurtured ventures from seed funding through product launch. While at Roche Diagnostics, Ms. Shoff also built a Global Internal Venturing Program, which the London School of Business praised in its book, Inventuring: Why Big Companies Must Think Small.

Henry Schein Management Efficiency

The company has return on total asset (ROA) of 0.0453 % which means that it generated a profit of $0.0453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0888 %, meaning that it created $0.0888 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities. As of March 18, 2024, Return On Capital Employed is expected to decline to 0.10. In addition to that, Return On Assets is expected to decline to 0.04. At present, Henry Schein's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 219.4 M, whereas Total Current Assets are forecasted to decline to about 2.4 B.
The company currently holds 2.74 B in liabilities with Debt to Equity (D/E) ratio of 0.29, which may suggest the company is not taking enough advantage from borrowing. Henry Schein has a current ratio of 1.8, which is within standard range for the sector. Debt can assist Henry Schein until it has trouble settling it off, either with new capital or with free cash flow. So, Henry Schein's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Henry Schein sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Henry to invest in growth at high rates of return. When we think about Henry Schein's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CEO Age

Leslie TriggOutset MedicalInc
53
Peter GassnerVeeva Systems Class
59
Jeffrey TangneyDoximity
51
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York. Henry Schein operates under Medical Distribution classification in the United States and is traded on NASDAQ Exchange. It employs 22000 people. Henry Schein (HSIC) is traded on NASDAQ Exchange in USA. It is located in 135 Duryea Road, Melville, NY, United States, 11747 and employs 25,000 people. Henry Schein is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Henry Schein Leadership Team

Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Ettinger, Senior Vice President - Corporate and Legal Affairs, Secretary
David McKinley, President Medical Group
Paul Rose, Senior Vice President Global Supply Chain
Norman Matthews, Independent Director
Philip Laskawy, Lead Independent Director
Steven Paladino, CFO, Executive VP and Executive Director
Ronald South, Senior CFO
Barry Alperin, Independent Director
Brad Connett, President - Henry Schein'sU.S. Medical Group
Shira Goodman, Independent Director
Lorelei McGlynn, Senior Vice President - Global Human Resources and Financial Operations
Bradley Sheares, Independent Director
Leonard David, Chief Compliance Officer, Senior Vice President
James Harding, CTO, Senior Vice President
Paul Brons, Independent Director
Lonnie Shoff, President and CEO of Global Animal Health and Strategic Partnerships Group
Gerald Benjamin, Chief Admin. Officer, Executive VP and Director
Bob Minowitz, President International Dental Group
Dianne Rekow, Director
Anne Margulies, Independent Director
Stanley Komaroff, Sr. Advisor
Mark Mlotek, Chief Strategic Officer, Executive VP and Director
Peter McCarthy, President - Global Animal Health Group
Bridget Ross, President of Global Medical Group
Kurt Kuehn, Independent Director
Christopher Pendergast, Senior Vice President CTO
James Breslawski, President, Executive Director and CEO of Global Dental Group
Elizabeth Rekow, Independent Director
Walter Siegel, Senior Vice President General Counsel
Graham Stanley, VP Officer
Jonathan Koch, Senior Vice President and CEO, Global Dental Group
Stanley Bergman, Executive Chairman and CEO
Joseph Herring, Independent Director
Olga Timoshkina, Chief Finance
Karen Prange, Executive Vice President; CEO of Global Animal Health, Medical and Dental Surgical Group
Carolynne Borders, Vice President - Investor Relations
Michael Racioppi, Senior Vice President Chief Merchandising Officer
Donald Kabat, Independent Director
Lawrence Bacow, Director
Louis Sullivan, Independent Director
Bradford Connett, Chief Group
Carol Raphael, Independent Director

Henry Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Henry Schein offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Henry Schein's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Henry Schein Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Henry Schein Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Henry Stock refer to our How to Trade Henry Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Henry Stock analysis

When running Henry Schein's price analysis, check to measure Henry Schein's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Henry Schein is operating at the current time. Most of Henry Schein's value examination focuses on studying past and present price action to predict the probability of Henry Schein's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Henry Schein's price. Additionally, you may evaluate how the addition of Henry Schein to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
FinTech Suite
Use AI to screen and filter profitable investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Henry Schein's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Henry Schein. If investors know Henry will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Henry Schein listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.62)
Earnings Share
3.16
Revenue Per Share
94.466
Quarterly Revenue Growth
(0.10)
Return On Assets
0.0453
The market value of Henry Schein is measured differently than its book value, which is the value of Henry that is recorded on the company's balance sheet. Investors also form their own opinion of Henry Schein's value that differs from its market value or its book value, called intrinsic value, which is Henry Schein's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Henry Schein's market value can be influenced by many factors that don't directly affect Henry Schein's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.